Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
190 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Metastatic Renal Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Metastatic Renal Cell Carcinoma Overview 8 Therapeutics Development 9 Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 9 Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 10 Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 11 Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 14 Metastatic Renal Cell Carcinoma - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Metastatic Renal Cell Carcinoma - Products under Development by Companies 18 Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 20 Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 21 Amgen Inc. 21 AstraZeneca PLC 22 Eli Lilly and Company 23 Novartis AG 24 Biocon Limited 25 Eisai Co., Ltd. 26 Exelixis, Inc. 27 Active Biotech AB 28 Bionomics Limited 29 Jiangsu Hengrui Medicine Co., Ltd. 30 Panacea Biotec Limited 31 Rexahn Pharmaceuticals, Inc. 32 Debiopharm International S.A. 33 Acceleron Pharma, Inc. 34 immatics biotechnologies GmbH 35 Argos Therapeutics, Inc. 36 Immutep S.A. 37 Syndax Pharmaceuticals, Inc. 38 Immune Design Corp. 39 NewLink Genetics Corporation 40 TVAX Biomedical, Inc. 41 TRACON Pharmaceuticals, Inc. 42 Beta Pharma, Inc. 43 Genor BioPharma Co., Ltd. 44 Kite Pharma, Inc. 45 Inbiopro Solutions Pvt. Ltd. 46 Conkwest, Inc. 47 Activartis Biotech GmbH 48 Epirus Biopharmaceuticals, Inc. 49 AlphaMab Co., Ltd 50 Metastatic Renal Cell Carcinoma - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 56 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 IMA-901 - Drug Profile 64 cabozantinib s-malate - Drug Profile 66 AGS-003 - Drug Profile 69 lenvatinib - Drug Profile 72 trebananib - Drug Profile 75 entinostat - Drug Profile 78 rilotumumab - Drug Profile 82 tasquinimod - Drug Profile 84 dalantercept - Drug Profile 86 RX-0201 - Drug Profile 88 BNC-105 - Drug Profile 90 Monoclonal Antibody Conjugated for Renal Cell Carcinoma - Drug Profile 92 AZD-2014 - Drug Profile 93 Vaccine for Metastatic Renal Cell Carcinoma - Drug Profile 95 Cell Therapy for Metastatic Renal Cell Carcinoma - Drug Profile 96 SHR-1020 - Drug Profile 97 AV0-113 - Drug Profile 99 TVI-Kidney-1 - Drug Profile 100 LY-2510924 - Drug Profile 101 panobinostat - Drug Profile 102 BNC-105P - Drug Profile 108 Debio-0932 - Drug Profile 110 everolimus - Drug Profile 112 CST-101 - Drug Profile 116 IMP-321 - Drug Profile 118 TRC-105 - Drug Profile 120 DC-AdGM-CAIX - Drug Profile 122 interleukin-15 - Drug Profile 124 G-305 - Drug Profile 125 Hyperacute For Renal Cancer - Drug Profile 127 bevacizumab biosimilar - Drug Profile 128 IBPM-002BZ - Drug Profile 129 Orellanine - Drug Profile 130 bevacizumab biosimilar - Drug Profile 131 bevacizumab biosimilar - Drug Profile 132 bevacizumab biosimilar - Drug Profile 133 bevacizumab biosimilar - Drug Profile 134 Recombinant Human Interleukin-2 - Drug Profile 135 BPI-3119 - Drug Profile 136 bevacizumab biosimilar - Drug Profile 137 Metastatic Renal Cell Carcinoma - Recent Pipeline Updates 138 Metastatic Renal Cell Carcinoma - Dormant Projects 175 Metastatic Renal Cell Carcinoma - Discontinued Products 176 Metastatic Renal Cell Carcinoma - Product Development Milestones 177 Featured News & Press Releases 177 Appendix 186 Methodology 186 Coverage 186 Secondary Research 186 Primary Research 186 Expert Panel Validation 186 Contact Us 187 Disclaimer 187
List of Tables Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2014 12 Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Late Stage Development, H2 2014 18 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Development, H2 2014 20 Products under Development by Companies, H2 2014 21 Products under Development by Companies, H2 2014 (Contd..1) 22 Products under Investigation by Universities/Institutes, H2 2014 23 Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2014 24 Metastatic Renal Cell Carcinoma - Pipeline by AstraZeneca PLC, H2 2014 25 Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2014 26 Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2014 27 Metastatic Renal Cell Carcinoma - Pipeline by Biocon Limited, H2 2014 28 Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2014 29 Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2014 30 Metastatic Renal Cell Carcinoma - Pipeline by Active Biotech AB, H2 2014 31 Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2014 32 Metastatic Renal Cell Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 33 Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2014 34 Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 35 Metastatic Renal Cell Carcinoma - Pipeline by Debiopharm International S.A., H2 2014 36 Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2014 37 Metastatic Renal Cell Carcinoma - Pipeline by immatics biotechnologies GmbH, H2 2014 38 Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2014 39 Metastatic Renal Cell Carcinoma - Pipeline by Immutep S.A., H2 2014 40 Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 41 Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2014 42 Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2014 43 Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2014 44 Metastatic Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 45 Metastatic Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H2 2014 46 Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2014 47 Metastatic Renal Cell Carcinoma - Pipeline by Kite Pharma, Inc., H2 2014 48 Metastatic Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 49 Metastatic Renal Cell Carcinoma - Pipeline by Conkwest, Inc., H2 2014 50 Metastatic Renal Cell Carcinoma - Pipeline by Activartis Biotech GmbH, H2 2014 51 Metastatic Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 52 Metastatic Renal Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H2 2014 53 Assessment by Monotherapy Products, H2 2014 54 Number of Products by Stage and Target, H2 2014 57 Number of Products by Stage and Mechanism of Action, H2 2014 61 Number of Products by Stage and Route of Administration, H2 2014 64 Number of Products by Stage and Molecule Type, H2 2014 66 Metastatic Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 141 Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2014 178 Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2014 179
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
